Steadvar — News without the noise

Privacy · Terms · About

© 2026 Steadvar. All rights reserved.

First Large-Scale Genetic Study of Cat Cancers Reveals Shared Drivers with Humans

ScienceHealth8h ago
Share

Similar Articles

Cancer Protein MYC Found to Aid DNA Repair, Helping Tumors Survive Treatment

HealthScience5/17/2026

New Platform Tracks How Genetic Errors Drive Disease, Reveals Shared Drug Resistance Pathways

ScienceHealth3d ago

Common Asthma Drug Shows Promise Against Multiple Cancer Types in Early Research

HealthScience2h ago

Research Links HOXD13 Protein to Melanoma Growth and Immune Evasion

HealthScience4/21/2026

Cancer Vulnerability Discovered in Vitamin B7-Dependent Enzyme

ScienceHealth4/20/2026

Researchers have published the first large-scale genetic profile of cancers in domestic cats, analyzing tumors from nearly 500 animals. The study found many of the same cancer-driving genes present in human cancers, including a key gene mutation linked to poorer outcomes in human breast cancer. This work represents a significant step in the 'One Medicine' approach, which aims to improve health outcomes across species.

Facts First

  • First large-scale genetic profile of cancers in domestic cats based on tumor samples from nearly 500 animals.
  • Many cancer-driving genes are shared between feline, human, and dog cancers.
  • FBXW7 gene mutations were most frequent in feline mammary tumors, appearing in more than half of samples.
  • Similarities were identified between feline and human cancers affecting multiple organ systems.
  • Certain chemotherapy drugs appeared more effective in cat mammary tumors carrying the mutated FBXW7 gene in tissue samples.

What Happened

Researchers published a study in the journal Science representing the first large-scale effort to genetically profile cancers in domestic cats. The international team analyzed tumor samples from nearly 500 domestic cats collected across five countries. They sequenced DNA from tissue samples previously collected by veterinarians for diagnostic purposes. The research found many of the same cancer-driving genes present in human and dog cancers. The FBXW7 gene was the most frequently altered gene in feline mammary tumors, with mutations appearing in more than half of the tumors studied.

Why this Matters to You

This research advances the 'One Medicine' approach, a collaborative strategy that encourages knowledge exchange between veterinary and medical researchers. The discovery of shared cancer-driving genes, like FBXW7, which is linked to poorer outcomes in human breast cancer, suggests that insights from feline health could potentially inform human cancer research and treatment strategies. The observation that certain chemotherapy drugs appeared to work better in cat mammary tumors carrying the mutated FBXW7 gene in tissue samples might lead to future investigations into more targeted therapies for both species.

What's Next

The findings provide a foundational genetic dataset for feline cancers, which could enable more precise diagnostics and treatment plans for cats in veterinary clinics. The international collaboration, which included institutions like the Wellcome Sanger Institute and the Ontario Veterinary College, is likely to continue exploring these shared genetic pathways. Further research may investigate whether the observed drug efficacy translates to improved outcomes in living animals, potentially benefiting both feline and human patients.

Perspectives

“
Scientific Researchers argue that the study fills a critical knowledge gap regarding feline cancer genetics and provides a valuable open resource for future comparative studies.
“
Medical Experts suggest that the research could lead to breakthroughs in precision oncology and new treatment possibilities for breast cancer in both animals and humans.
“
Comparative Medicine Specialists emphasize that the cross-species data flow allows for insights into how environmental exposures and shared human-animal environments influence cancer risk.
“
Data Analysts highlight that the ability to assess drug responses across various tumor types at such a large scale was only made possible through the access to a massive set of donated tissues.